Skip to main content
OpenTrials
Completed

NCT Number: NCT00343239

Docetaxel in Locally Advanced Gastric Adenocarcinoma

Study objectives:

To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Sanofi-Aventis Administrative Office

Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven gastric adenocarcinoma diagnosis
  • Selected Stage IIB (T3N0M0), Stage IIIA (T2aN2M0, T2bN2M0, T3N1M0, T4N0M0), Stage IIIB (T3N2M0) and selected Stage IV (all T4 , NM0, all TN3M0's). Clinical staging performed with endoscopic ultrasound and CT. Laparotomy or laparoscopy is preferred to determine resectability and peritoneal involvement.
  • ECOG performance status between 0 and 2
  • Acceptable hematological profile :
  • WBC (White Blood Cell) count ≥4000/mm3
  • Platelet count ≥100 000 mm3
  • Hemoglobin ≥9 g/100 mL (if lower, may be included following transfusion)
  • Adequate renal function
  • Serum creatinine <1.2 mg/dl or calculated creatinine clearance in 24-hours urine >60 mL/min.
  • Adequate hepatic function
  • Bilirubin < UNL
  • Transaminases (ALT, AST) <2.5 x UNL
  • Alcaline phosphatase <2.5 x UNL
  • Adequate pulmonary function
  • Adequate cardiac function
  • No prior chemotherapy for gastric cancer

Exclusion criteria

  • Other histological types of gastric cancer (leiomyosarcoma, lymphoma) than adenocarcinoma
  • Pregnant or lactating patients
  • Patients with brain, bone or other metastases; peritoneal involvement
  • Other serious underlying medical conditions which could impair the ability of the patient to participate in the study (congestive heart failure, serious arrhythmia, uncontrolled diabetes mellitus, serious neuropathy), history of myocardial infarction within 6 months prior to study entry
  • Previous or other current malignancies, with the exception of carcinoma of the cervix uteri or breast cancer or basal cell skin cancer and a disease-free period shorter than 5 years
  • Active infection and other serious disease
  • Any other experimental drugs within a 4-week period prior to the study
  • Contraindications for the use of any study drug (e.g. history of hypersensitivity to the contents of the study drugs)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

docetaxel

Drug

Formulation: infusion solution

Route of administration: IV infusion on the first day of each 21-day cycle

Dose regimen: 75 mg/m2

Cisplatin

Drug

Formulation: infusion solution

Route of administration: IV infusion on the first day of each 21-day cycle

Dose regimen: 75 mg/m2

Fluorouracil

Drug

Formulation: infusion solution

Route of administration: IV infusion on the first day of each 21-day cycle

Dose regimen: 750 mg/m2/day for 5 days

Primary outcomes

  1. To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.

    Time frame: 3 cycles

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study

Acronym: NEOTAX

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Jun 22, 2006
Registry last updated
Nov 4, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.